Trials / Recruiting
RecruitingNCT07247266
Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)
A Phase 1b, Open-label, Single-arm Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- Akros Pharma Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-162 administered once daily for 2 weeks in subjects with cryopyrin-associated periodic syndrome (CAPS)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JTE-162 | Tablets containing JTE-162 |
Timeline
- Start date
- 2026-02-02
- Primary completion
- 2026-06-01
- Completion
- 2026-12-01
- First posted
- 2025-11-25
- Last updated
- 2026-02-09
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT07247266. Inclusion in this directory is not an endorsement.